💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Apollo Hospitals Enterprise Limited is an integrated healthcare company. It is engaged in the business of providing hospital services and selling pharma and wellness products through a network of pharmacies, including the operation of multidisciplinary private hospitals,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, trading cheap versus its own history.
Apollo Hospitals is scored on the pharma / healthcare framework. It keeps a slim 7.9% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.43× reported profit. Free cash flow is worth about 0.6% of its market value.
Over the last 3 years revenue compounded at 15%/yr and profit at 33%/yr. Book value itself has compounded 15%/yr — the hallmark of a genuine compounder. Return on equity is an elite 21.1%. In the latest quarter profit grew 11% versus the prior quarter.
At 63× earnings, the stock sits at the 8th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price already implies ~22%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 51.95 | 75.62 | better |
| P/B | 11.45 | 3.49 | worse |
| EV/EBITDA | 28.53 | 19.95 | worse |
| ROE | 21.14 | — | — |
| ROCE | 18.94 | 10.81 | better |
| ROA | 9.65 | 3.84 | better |
| Quick Ratio | 0.98 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
| Aster DM Healthcare | 171.4 | 14.8 | 8.5% |
Revenue has grown every year across all 4 financial years shown. 15% CAGR over 3 years — steady double-digit compounder.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (33% vs 15%) — margin expansion is at work. The latest year saw a +33% swing — check if it's a one-off or structural.
Operating margin has expanded from 7% to 10% — the business is keeping more of each rupee earned.
ROE at 20% — the business earns well above its cost of equity. High ROE despite single-digit margins — an asset-turn play with high capital velocity. Capital efficiency improving — ROE up 6pp across the window.
EPS has grown every year — each share earns more than the last, consistently. 33% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.4× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 7% sequentially — momentum is building.
Profit jumped 11% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold just 28.0% — widely held; sentiment-driven.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.